Amorfix Life Sciences Ltd. Announces Breakthrough Scientific Discovery and Provides Update for Its Ovarian Cancer Therapeutic Antibody Program
Published: Apr 09, 2013
TORONTO, April 9, 2013 /CNW/ - Amorfix Life Sciences announced today it has completed a study that shows that the treatment of cancer cells with chemotherapeutic agents increases the amount of misfolded prion protein at the cell surface, and the subsequent binding of anti-prion protein antibodies. The increased expression is specific to tumor cells and is not seen on normal ovarian cells. In addition, the Company reports the completion of the first in a series of studies with its anti-misfolded prion protein antibody in animal models of ovarian cancer with promising preliminary results on reducing tumor volume.